

1 **The association of the *ACTN3* R577X and *ACE* I/D polymorphisms with**
2 **athlete status in football: a systematic review and meta-analysis**

3 Alexander B. T. McAuley¹, David C. Hughes¹, Loukia G. Tsaprouni¹, Ian
4 Varley², Bruce Suraci³, Thomas R. Roos⁴, Adam J. Herbert¹, and Adam L. Kelly¹

5 *¹Faculty of Health, Education and Life Sciences, Birmingham City University, Birmingham,*
6 *West Midlands, United Kingdom; ²Department of Sport Science, Nottingham Trent University,*
7 *Nottingham, United Kingdom; ³Academy Coaching Department, AFC Bournemouth,*
8 *Bournemouth, United Kingdom; ⁴The International Academy of Sports Science and*
9 *Technology (AISTS), University of Lausanne, Lausanne, Switzerland*

10

11 Correspondence: A. McAuley, Department of Life Sciences, Birmingham City University,
12 City South Campus, Westbourne Road, Edgbaston, B15 3TN, UK. E-mail:
13 Alex.Mcauley@mail.bcu.ac.uk

14 **The association of the *ACTN3* R577X and *ACE* I/D polymorphisms with**
15 **athlete status in football: a systematic review and meta-analysis**

16

17 The aim of this review was to assess the association of *ACTN3* R577X and *ACE* I/D
18 polymorphisms with athlete status in football and determine which allele and/or genotypes
19 are most likely to influence this phenotype via a meta-analysis. A comprehensive search
20 identified 17 *ACTN3* and 19 *ACE* studies. Significant associations were shown between
21 presence of the *ACTN3* R allele and professional footballer status (OR = 1.35, 95% CI:
22 1.18-1.53) and the *ACE* D allele and youth footballers (OR = 1.18, 95% CI: 1.01-1.38)
23 compared to a control group. More specifically, the *ACTN3* RR genotype (OR = 1.48, 95%
24 CI: 1.23-1.77) and *ACE* DD genotype (OR = 1.29, 95% CI: 1.02-1.63) exhibited the
25 strongest associations, respectively. These findings may be explained by the association of
26 the *ACTN3* RR genotype and *ACE* DD genotype with power-orientated phenotypes and the
27 relative contribution of power-orientated phenotypes to success in football. As such, the
28 results of this review provide further evidence that individual genetic variation may
29 contribute towards athlete status and can differentiate athletes of different competitive
30 playing statuses in a homogenous team-sport cohort. Moreover, the *ACTN3* R577X and
31 *ACE* I/D polymorphisms are likely (albeit relatively minor) contributing factors that
32 influence athlete status in football.

33

34 Keywords: Soccer; Team-Sport; Genetics; SNP; Genomics.

35 1 Introduction

36 Actinin alpha 3 (ACTN3), a member of the actin family, is a sarcomeric protein which is greatly
37 expressed in muscle tissue ¹. A function of the ACTN3 protein involves crosslinking fast-twitch (type
38 II) actin filaments in skeletal muscle fibres ². Thus, the expression of the ACTN3 protein in glycolytic
39 skeletal muscle is thought to be a contributing factor to the generation of powerful and explosive muscle
40 contractions; through optimal coordination of type II muscle fibres ³. The coding of the ACTN3 protein
41 is controlled by the *ACTN3* gene, located on chromosome 11q13.2. A common genetic variant in the
42 *ACTN3* gene has been identified which significantly alters the production of the ACTN3 protein ⁴. The
43 genetic variation is a nonsense single nucleotide polymorphism (SNP) which can introduce a premature
44 stop codon within the gene at position 577 (rs1815739) ⁵. Cytosine is the most common nucleotide at
45 this position (i.e., CGA), which encodes the amino acid, arginine (R) ². Alternatively, thymine can be
46 possessed by an individual (i.e., TGA), producing the stop codon (X); potentially resulting in an
47 individual being deficient in ACTN3 ⁴. As the *ACTN3* gene portrays a role in force production, it has
48 been hypothesised that the performance of activities requiring extensive force production (i.e.,
49 sprinting, jumping, weightlifting) would be influenced by whether an individual possesses the R allele
50 or RR genotype. Many studies have reported that either the RR genotype was over-represented, or the
51 XX genotype was underrepresented, in power-related sports (e.g., 100m sprint, rowing, speed skating,
52 artistic gymnastics, sprint swimming, Olympic weightlifting) across American, Polish, Finnish, Italian,
53 Japanese, Israeli, and Russian cohorts ⁶⁻¹⁵. Indeed, Ma and colleagues ¹⁶ conducted a meta-analysis on
54 23 studies involving power and endurance athletes and discovered that the R allele was only associated
55 with power athletes. Moreover, a recent meta-analysis on solely power athletes reported similar
56 associations between the R allele and power athletes across 38 studies ¹⁷.

57 Another commonly investigated gene in sport performance is the angiotensin I converting
58 enzyme (*ACE*) gene. The angiotensin I converting enzyme catalyses the degradation of the inactive
59 decapeptide angiotensin I, and subsequently generates the physiologically active peptide, angiotensin
60 II; an oligopeptide of eight amino acids that binds to specific receptors in the body affecting several
61 systems ^{18,19}. Angiotensin II can constrict blood vessels and stimulate aldosterone production, resulting
62 in increased blood pressure, thirst, or the dire for salt. As such, the ACE enzyme is the most crucial
63 component of the renin-angiotensin system (RAS), as it is a potent vasopressor and aldosterone-
64 stimulating peptide which regulates blood pressure and fluid-electrolyte balance ²⁰. A polymorphism
65 has been identified within intron 16 of the *ACE* gene, located on chromosome 17q23.3
66 (NC_000017.11), which results in a substantial variation of RAS activity ^{21,22}. The polymorphism is
67 known as an insertion/deletion (indel) polymorphism, with the insertion (I allele) and deletion (D allele)
68 representing the presence and absence of a 287-bp Alu-sequence respectively. Specifically, the I allele
69 has been associated with lower serum and tissue ACE activity, alongside an increased percentage of
70 slow-twitch (type I) muscle fibres; whilst the D allele has been associated with higher circulating and

71 tissue ACE activity, alongside greater strength and muscle volume and an increased percentage of type
72 II muscle fibres ²¹⁻²³. In the context of sport, the I allele has been frequently associated with elite
73 endurance performance. Specifically, higher I allele frequencies have been reported in middle- and
74 long-distance rowers, swimmers, road-cyclists, runners, mountaineers, cross-country skiers, and tri-
75 athletes across a range of diverse cohorts (e.g., British, Australian, Croatian, Russian, Spanish, Italian,
76 Turkish, Polish, Japanese, Indian) ²⁴⁻³³. Indeed, during the meta-analysis of Ma and colleagues ¹⁶, the
77 authors also assessed the influence of the *ACE* I/D polymorphism on endurance athletes over 25 studies,
78 reporting that the II genotype was significantly associated with endurance athletes. However, the
79 authors found no association between the *ACE* I/D polymorphism and power athletes. This may have
80 been due to the large heterogeneity observed between studies ($I^2 = >75\%$), most likely a result of not
81 analysing the power athletes independently based upon ethnicity. Indeed, a more recent meta-analysis
82 did conduct an ethnic specific analysis of power athletes and reported significant associations with the
83 *ACE* D allele ³⁴.

84 The collective results on the associations of the *ACTN3* R577X and *ACE* I/D polymorphisms,
85 with athletic performance, complicate the implications for sports which require both power and
86 endurance related traits, such as football. Football is an intermittent sport which requires optimal
87 utilisation of both the aerobic and anaerobic systems ^{35,36,37,38}; and as such, predicting whether a power
88 or endurance-orientated allelic variant may be preferable is not straightforward. Therefore, genetic
89 association studies began to investigate whether a power or endurance-orientated genotype was more
90 important in football by analysing polymorphisms such as *ACTN3* R577X and *ACE* I/D ³⁹⁻⁴¹. Moreover,
91 studies began to assess if there was a difference between football players of various competitive playing
92 levels (i.e., elite, non-elite; professional [PRO], non-professional [NP]) and controls (CON), in order to
93 determine if *ACTN3* R577X or *ACE* I/D were associated with athlete status ⁴²⁻⁴⁴. Currently, there is no
94 general consensus on the importance of *ACTN3* or *ACE* in footballers, with studies reporting positive,
95 negative, and contrasting allelic associations ³⁹⁻⁴⁴. This is most likely because each gene or genotype
96 has a small contribution to sporting performance and is dependent on numerous inter-individual
97 variations (e.g., ethnicity and competitive playing level) ^{45,46}. As a result, studies require large
98 homogenous sample sizes in order to have sufficient statistical power and demonstrate significant
99 associations and replications ^{45,47}. However, studies within football genomics have notoriously small
100 sample sizes and many are heterogenic multi-sport studies; mainly due to the unique population and
101 limited access available ⁴⁸. Therefore, to overcome the limitation of sample sizes and heterogeneity, a
102 meta-analysis can be used to pool the results of single homogenous studies together ⁴⁷. As such, the aim
103 of this study was to assess if the *ACTN3* R577X and/or *ACE* I/D polymorphism are associated with
104 athlete status in football by conducting a systematic review and meta-analysis.

105 **2 Methodology**

106 **2.1 Search Strategy and Inclusion/Exclusion Criteria**

107 In accordance to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA)
108 guidelines⁴⁹, the following search strategy was implemented. A comprehensive search of the Pubmed,
109 SPORTDiscus, and MEDLINE databases was conducted on March 3rd 2020. For *ACTN3* the following
110 Boolean search was used: ((football) OR (soccer)) AND (actn3) OR (alpha-actinin-3) OR (actinin-
111 alpha-3) OR (R577X) OR (rs1815739)). For *ACE* the following Boolean search was used: ((football)
112 OR (soccer)) AND (ace) OR (angiotensin I converting enzyme) OR (rs1799752) OR (rs13447447) OR
113 (rs4341) OR (rs4646994)). Additionally, Google Scholar was searched using word combinations of the
114 aforementioned Boolean searches, with no year restriction placed on any search. Furthermore, reference
115 lists of the identified articles were searched for additional relevant studies. At the initial screening stage
116 studies were included if they: (1) were primary cohort or case-control investigations; (2) presented
117 *ACTN3* R577X or *ACE* I/D genotype frequencies of footballers in isolation; and (3) were published in
118 the English language. Therefore, studies were excluded if they: (1) were reviews; (2) presented *ACTN3*
119 R577X or *ACE* I/D genotype frequencies of footballers combined with other sports; and (3) were
120 published in a language other than in English.

121 **2.2 Data Extraction and Analysis**

122 We extracted the following data from all studies: first author's name and year of publication; number
123 of footballers and CON; nationality and ethnicity; gender; age range; competitive playing level; type of
124 study (cohort or case-control); and distribution of genotype frequencies in footballers and CON.
125 Extracted data was then analysed in the following order: 1) pooled genotype frequencies of case-control
126 studies in isolation; 2) pooled genotype frequencies of case-control studies combined with cohort
127 studies (with an ethnically matched independent CON population added); and 3) sub-group analysis of
128 ethnicity, gender, and level of competition. Independent CONs were added to cohort studies from the
129 1000 genomes database (<https://www.internationalgenome.org>) or an independent non-included study.
130 Each cohort study was assigned a CON which was not used by any other study in the analysis to bolster
131 the number of unique individuals and decrease selection bias. All of the included CON were also
132 subjected to risk of bias before being included.

133 **2.3 Risk of Bias**

134 After initial primary inclusion, all studies were subjected to Hardy–Weinberg equilibrium (HWE) via
135 chi-square (significance level $P < 0.05$); culminating in the removal of all studies violating this
136 significance threshold, as deviations from HWE in a CON group can indicate potential genotyping
137 errors, selection bias and stratification⁵⁰. Furthermore, as each study is tested for HWE, Benjamini-
138 Hochberg false discovery rate (FDR) is used to correct p-values⁵¹. Additionally, as this review only
139 uses published studies, publication bias could be a limiting factor. Therefore, Egger's test⁵² in

140 combination with funnel plots⁵³ were used to identify if publication bias was present and potentially
141 skewing results (significance level $P < 0.05$).

142 **2.4 Statistical Analysis**

143 To measure the strength of the association between the *ACTN3* R577X and *ACE* I/D polymorphisms
144 and football players, odds ratios (OR), 95% confidence intervals (CI), and forest plots were used via
145 either a fixed-effects model or random-effects model to identify the individual and pooled effects of the
146 studies. Determining which model was appropriate for each analysis was based on the level of
147 heterogeneity revealed via the I^2 ($< 50\%$ = fixed-effects model; $> 50\%$ = random-effects model) and
148 Cochran's Q ⁵⁴ statistical test (significance level at $P < 0.05$). Four genetic models were used to assess
149 genotype and allele differences between football players and CONs: (a) allele contrast; (b) recessive;
150 (c) dominant; and, (d) over-dominant. Additionally, pair-wise comparisons were also conducted.
151 Finally, a sensitivity analysis was conducted via a leave-one-out approach in order to test the robustness
152 of results⁵⁵. All analyses were conducted using the MetaGenyo online Statistical Analysis System
153 software (<http://bioinfo.genyo.es/metagenyo/>)⁵⁶.

154 **3 Results**

155 **3.1 Search Process**

156 The systematic search processes initially identified 588 studies (*ACTN3*, $n = 290$; *ACE*, $n = 298$).
157 Following the removal of duplicates and the screening of titles and abstracts, full-text assessment
158 commenced; culminating in 17 *ACTN3* and 19 *ACE* studies being judged as adequately meeting the
159 predetermined inclusion criteria and subsequently being included in the final analysis (see Figure 1 for
160 full systematic search process).

161 ****Insert **Figure 1**. near here****

162 **3.2 Study Characteristics**

163 The 17 *ACTN3* studies consisted of nine case-control and eight cohort studies respectively. There were
164 a total of 1759 football players included across all studies (aged 10-37 years), with sample sizes ranging
165 from 25-353. The most frequently studied nationality was Brazilian ($n = 850$), whilst the most
166 frequently studied ethnicity was Caucasian ($n = 587$). Eleven studies included PRO players ($n = 713$;
167 aged 17-37 years); four studies included NP players ($n = 447$; aged 14-30 years); and, two included
168 both PRO and NP players ($n = 599$; aged 10-27 years). The 19 *ACE* studies consisted of 15 case-control
169 and four cohort studies. There were a total of 1925 football players included across all studies (aged 10-
170 27 years), with sample sizes ranging from 25-353. The most frequently studied nationality was Brazilian
171 ($n = 709$), whilst the most frequently studied ethnicity was Caucasian ($n = 802$). Ten studies included
172 PRO players ($n = 674$; aged 17-26 years); seven studies included NP players ($n = 652$; aged 15-21
173 years); and, two included both PRO and NP players ($n = 599$; aged 10-27 years).

174 3.3 Risk of Bias

175 Fifteen of the originally included 17 *ACTN3* studies remained after risk of bias assessment. The studies
176 excluded, with reasons for exclusion, were as follows: (1) Massidda et al.⁵⁷ failed HWE assessment;
177 and, (2) La Montagna et al.⁵⁸ failed to provide the specific nationality and ethnicity of the footballers,
178 thus an ethnically-matched CON could not be added. Seventeen of the originally included 19 *ACE*
179 studies remained after risk of bias assessment. The following studies were excluded due to failing HWE
180 assessment: Gineviciene et al.⁵⁹ and Galeandro et al.⁴¹. In addition, the Bulgarian sub-cohort of
181 Andreeva et al.⁶⁰ was excluded from analysis due to also failing HWE assessment. In all genetic
182 comparison models that identified a significant association with *ACTN3* and *ACE*, funnel plots did not
183 reveal any signs of asymmetry and Egger's test did not detect a significant indication of publication
184 bias.

185 3.4 Main Analysis

186 Several significant associations were observed between the *ACTN3* R577X polymorphism and genetic
187 comparison models with case-control studies in isolation: (1) allele contrast; (2) recessive; (3)
188 dominant; (4) RR vs. XX; and, (5) RR vs. RX. In addition, similar associations with the same genetic
189 models were also observed in case-control studies combined with cohort studies; with the only
190 exception being the additional significant association of RX vs. XX. The strongest association observed
191 in both case-controls in isolation and combined with cohorts was RR vs. XX (see Table 1 for ORs and
192 CIs of each *ACTN3* comparison). Sensitivity analysis assessed the robustness of the results and revealed
193 that no study significantly altered pooled ORs. Conversely, no significant associations were observed
194 between the *ACE* I/D polymorphism with case-controls in isolation or combined with cohorts using any
195 genetic comparison model (see Table 2 for ORs and CIs of each *ACE* comparison).

196 3.4.1 Sub Analyses

197 The first sub-analysis assessed the independent associations of PRO players and NP players vs. controls
198 (CON). Several significant associations were observed between the *ACTN3* R577X polymorphism and
199 genetic comparison models in PROs: (1) allele contrast; (2) recessive; (3) dominant; (4) RR vs. XX;
200 and, (5) RR vs. RX. The strongest association observed was RR vs. XX. No significant associations
201 were observed between the *ACTN3* R577X polymorphism and genetic comparison models in NPs vs.
202 CON. Conversely, no significant associations were observed between the *ACE* I/D polymorphism and
203 PRO players. However, several significant associations were observed between the *ACE* I/D
204 polymorphism and NP players: (1) allele contrast; (2) dominant; and, (3) ID vs. DD.

205 The second sub-analysis assessed the independent influence of ethnicity and nationality on
206 associations. Due to the variance in geographical ancestry, Caucasian and Brazilian were the only
207 ethnicity and nationality eligible for analysis. Several significant associations were observed between
208 the *ACTN3* R577X polymorphism and genetic comparison models in Caucasians: (1) allele contrast;

209 (2) recessive; (3) dominant; and, (4) RR vs. XX. Likewise, several significant associations were also
210 observed between the *ACTN3* R577X polymorphism and genetic comparison models in Brazilians: (1)
211 allele contrast; (2) dominant; (3) RR vs. XX; and, (4) RX vs. XX. The strongest association observed
212 in both Caucasians and Brazilians was RR vs. XX. Conversely, no significant associations were
213 observed between the *ACE* I/D polymorphism and Caucasians or Brazilians.

214 ****Insert **Table 1.** near here****

215 ****Insert **Table 2.** near here****

216 **4 Discussion**

217 The aim of this study was to assess if the *ACTN3* R577X and/or *ACE* I/D polymorphism were associated
218 with athlete status in football; and if so, determine which allele and/or genotypes are most likely to
219 influence this phenotype via a meta-analysis. To the author's knowledge this is the first review to do
220 this within football; and moreover, it is the first meta-analysis in a homogenous team-sport cohort.

221 **4.1 Main Analysis**

222 Following meta-analysis, this review identified several associations between the *ACTN3*
223 R577X polymorphism and all football players (PRO & NP combined) vs. CON. In summary, the main
224 associations were observed in football players possessing the R allele, with the strongest association
225 being the RR vs. XX genotype. These associations were observed in case-control studies in isolation
226 and remained similar with the addition of cohort studies. Although, with the significant increase in
227 sample size from cohort studies the CI was reduced, possibly indicating a more accurate estimation.
228 The only notable difference between genetic comparison models was that the RX vs. XX pair-wise
229 comparison was statistically significant with cohorts added vs. non-significant in case-controls in
230 isolation. Therefore, only the over-dominant model remained non-significant in both case-control
231 studies in isolation and with the addition of cohort studies; most likely due to the strength of the
232 association of the RR genotype. As such, the results of this analysis showcase that in football players,
233 similar to power athletes, there is an overrepresentation of the *ACTN3* RR genotype. For instance, this
234 can be illustrated by the similar recessive model and dominant model findings of the present study and
235 Ma and colleagues¹⁶, respectively. This can likely be explained by the combination of several factors:
236 (1) the number and frequency of powerful actions performed in a game (i.e., 1000-1400 acyclical bursts
237 of activity, including; jumps, tackles, shots at goal, changes of direction, and, sprints), with a high-
238 intensity sprint occurring every ~70s^{61,62}; (2) the contribution of the ability to repeat higher intensity
239 actions to success in football (i.e., league position, goals scored, goals prevented, duel success)^{63,64};
240 and, (3) the association of the RR genotype with power-orientated phenotypes (i.e., vertical jumping
241 and 10-30m sprints)^{65,66}. However, it is important to recognise that there are many other genetic
242 polymorphisms, with each likely influencing performance to a limited extent^{45,46}. Therefore, football

243 players, power athletes, and indeed other team-sports, may possess contrasting allele and genotype
244 frequencies in other polymorphisms. Hence, the results of this review only indicate a difference between
245 football players and non-athletic CONs. However, this difference appears to be greatly mediated by
246 competitive playing level, which may have contributed to the heterogeneity present between *ACE*
247 studies; and as a result, the non-significant associations between *ACE* and PRO & NP players combined.
248 Indeed, the results of the subsequent sub-analysis on competitive playing level revealed that *ACE* may
249 play an important role in determining athlete status earlier in athlete development. Therefore, although
250 *ACE* was not associated with athlete status in the main analysis, it is still an important genetic variant
251 in football, depending on specific competitive playing levels.

252 4.2 Sub-Analyses

253 The importance of the competitive playing level of footballers in this review was assessed via
254 separating PRO players and NP players. PRO players were classified as players that studies specifically
255 described as playing at a professional level, whereas NP players were classified as players playing at a
256 semi-professional, amateur, or youth level. This particular method of categorisation was chosen, as
257 opposed to elite vs. non-elite, to circumvent the problematic classification issue of ‘eliteness’ (i.e., what
258 constitutes elite status and how do we define it?)^{67,68}. For example, players may be internationals who
259 represent their country (normally classed as elite), however what if their country is near the bottom of
260 the international rankings? Furthermore, players may play for a European club positioned 1st in their
261 country’s highest league (normally classed as elite), but what if the country and club both have a low
262 UEFA coefficient ranking? Moreover, how do we define the highest performing youth players? Given
263 that no irrefutable solution has been provided and no general consensus has been agreed, the term ‘elite’
264 is still inconsistently utilised in the literature to describe varying standards of performance^{67,68}.
265 Therefore, to reduce between-study-heterogeneity, the authors chose to compare PROs and NPs
266 (limitations of this approach are discussed in section 4.3).

267 Firstly, the results of this analysis revealed that the *ACTN3* R577X polymorphism was
268 associated with PRO players vs. CON. However, no statistically significant difference was observed
269 between NP players and CON. Moreover, the strength of the association between the R allele, and
270 specifically the RR genotype, was even stronger in PRO players when separated from NP players. As
271 such, these results indicate that the R allele is a likely (albeit small) contributing factor towards attaining
272 PRO status in football. Secondly, whilst the *ACE* I/D polymorphism was not associated with PRO
273 players vs. CON, it was associated with NP players vs. CON. To be specific, NP players were more
274 likely to possess a D allele or DD genotype. This is perhaps more easily demonstrated via inverse
275 statistical analysis: (1) D vs. I (OR = 1.18, 95% CI: 1.01-1.38); (2) DD vs. DI+II (OR = 1.29, CI: 1.02-
276 1.63); and, (3) DD vs. DI (OR = 1.32, CI: 1.03-1.69). Interestingly, the NP players consisted solely of
277 youth players in the *ACE* I/D studies (n = 652; aged 15-21 years) showcasing that the D allele is only
278 overrepresented specifically in youth football. Furthermore, the differences between PROs and NPs

279 may have increased further given that Egorova and colleagues⁴² was not included in this analysis, due
280 to not displaying the individual genotype frequencies of PRO and NP players in their study. However,
281 the authors did report that when separated by competitive playing level, only elite players displayed a
282 significantly higher frequency of the *ACTN3* R allele compared to CON (81.1%, $P < 0.001$); whilst
283 conversely, only youth players displayed a significantly higher frequency of the *ACE* D allele compared
284 to CON (78.8%, $P < 0.001$). As such, the observed cumulative evidence suggests that whilst possessing
285 the *ACE* D allele is potentially more beneficial to young players, the *ACTN3* R allele is the only allele
286 which likely has a (minor) role in attaining PRO status (see Figure 2). However, it is important to note
287 the use of terms such as “albeit small” and “minor” when interpreting these findings. Polymorphisms
288 account for very little of the inter-individual variance in complex traits such as athlete status⁴⁵. Indeed,
289 even a combination of 97 polymorphisms (at $P = 5 \times 10^{-8}$ or better) could only account for 2.7% of body
290 mass index variance between individuals⁶⁹. Therefore, as evidenced by the relatively small odds ratios
291 in this study, *ACTN3* and *ACE* similarly play a minor role in determining athlete status in football.

292 ****Insert **Figure 2.** near here****

293 The explanation for the observed associations between the *ACE* D allele and *ACTN3* R allele
294 with youth and PRO players respectively is challenging. Both alleles have been previously associated
295 with strength/power orientated sports and general strength/power characteristics (i.e., increased
296 percentage of type II muscle fibres; strength; and, muscle mass)^{13,23}. More specifically, in football
297 cohorts both alleles have been positively associated with greater countermovement and squat jump
298 performance, and faster 10m, 20m, and 30m sprint times^{65,66}. As such, both alleles appear to be
299 associated with the same side of the endurance-power continuum in football. Therefore, it is interesting
300 that each allele is independently associated with different competitive playing levels. However, perhaps
301 the categorisation method employed to distinguish competitive playing levels in this review could
302 possibly be responsible. For example, whilst heterogeneity between studies in the PRO vs. NP analysis
303 was mostly small, the age of NPs in *ACTN3* ranged from 14-30 years; whereas the age of NP players
304 in *ACE* ranged from 15-21 years. As such, it is possible that the NP *ACE* players had greater
305 performance levels than the NP *ACTN3* players, as the NP *ACE* players may play at the highest youth
306 level in their respective age groups; whilst the *ACTN3* players may not. Indeed, several previous studies
307 have demonstrated that ‘elite’ youth players, aged 14-17 years, have outperformed non-elite players in
308 acceleration, speed and jumping assessments^{70,71}. Although, it could be argued that grouping young
309 players (14-17 years) as elite and non-elite is not appropriate as factors such as maturation status may
310 influence performance more than *ACTN3* or *ACE* genotype. However, in truth, numerous potential
311 explanations exist, including: (1) differences in competitive performance levels; (2) variations in
312 geographical ancestry; (3) disparities in the distributions of players relative to their on-field position
313 within samples; (4) distinct methods of genotyping; (5) individual gene-gene interactions; and, (6)
314 separate gene-environment interactions. Moreover, it is also important to note that the *ACE* gene is part

315 of a very complex pathway, with several interactions that can influence its activity; whilst *ACTN3*
316 represents the presence/absence of a structural protein^{18,19}. As such, the specific cause of the distinction
317 between the *ACTN3* R577X and *ACE* I/D polymorphisms with PRO and NP players requires further
318 research to elucidate these findings.

319 In addition to competitive playing level, sub-analysis also assessed the influence of ethnicity
320 and geographical ancestry on observed associations. Therefore, studies, and samples within studies,
321 were separated based upon their reported ethnic heritage and nationality. After separation, Caucasians
322 and Brazilians collectively represented 81% and 79% of *ACTN3* and *ACE* studies respectively.
323 Therefore, only these could be assessed via comparison analysis. Firstly, in relation to the *ACE* I/D
324 polymorphism, no significant associations were observed in either Caucasians or Brazilians. However,
325 in relation to the *ACTN3* R577X polymorphism, several significant associations were observed in both
326 Caucasians and Brazilians between the R allele and football players vs. CON. However, in models with
327 significant associations in both Caucasians and Brazilians (allele contrast, dominant, RR vs. XX),
328 Caucasians displayed higher ORs. This suggests the R allele, and more significantly the RR genotype,
329 appear to be of greater importance to footballers of Caucasian heritage. This suggestion is bolstered by
330 the significant associations observed solely between Caucasians and a recessive model, and between
331 Brazilians and the pair-wise comparison of the RX vs. XX genotypes. This reveals that the RX genotype
332 may be more associated with footballing status in Brazilians, whilst the RR genotype may be more
333 associated with footballing status in Caucasians.

334 The possible cause of the disparities in ORs between the R allele in Brazilians and Caucasians
335 may be related to the ethnic diversity of the Brazilian population; and more specifically, the proportion
336 of individuals with African ancestry. Individuals of African ancestry have greater frequencies of the
337 RR genotype (~78%) and significantly lesser frequencies of the XX genotype (~1%), irrespective of
338 athlete status, compared to the estimated frequencies of the world population (RR ~40%; XX ~18%)⁷²⁻
339 ⁷⁴. As such, the *ACTN3* R577X polymorphism does not differentiate elite athletes from CON of African
340 ethnicity in either power or endurance-orientated sports^{72,73}. Using ancestry informative markers,
341 previous studies have reported that the Brazilian population are formed of ~65% European SNPs, ~22%
342 African SNPs, and ~13% Amerindian SNPs⁷⁵. Furthermore, these proportions vary in each independent
343 region of Brazil. For example, it is estimated that the population of Rio de Janeiro is formed of ~55%
344 European SNPs, ~31% African SNPs, and ~14% Amerindian SNPs⁷⁶. As such, given the genetic
345 similarity of the Brazilian population with the genetic profile of African ethnicities, this potentially
346 explains why the RR genotype may contribute to footballing status in Brazil to a lesser extent.

347 **4.3 Strengths and Limitations**

348 This study's findings are reinforced due to the small-moderate heterogeneity identified between
349 studies. Only two of the 28 total measurements regarding *ACTN3* displayed an I^2 value over 50% and

350 violated Cochran's Q statistical threshold ($P < 0.05$); although neither of these two measurements
351 displayed a statistically significant result. Likewise, neither of the three associations identified between
352 the *ACE* I/D polymorphism and NP players displayed significant heterogeneity. Furthermore, no
353 suggestion of publication bias was identified regarding the observed significant associations, through
354 analysis of funnel plots or Egger's test ($P < 0.05$).

355 This review is not without limitations and each must be duly considered when interpreting the
356 findings. Firstly, this review attempted to include both male and female football players, but
357 unfortunately the authors could only locate one study involving female players⁶⁰ which met the pre-
358 defined inclusion criteria. Therefore, the results from this review mainly apply to male football players.
359 Secondly, the ethnic and geographic implications of this review mainly concern Brazilians and
360 Caucasians, due to both representing the majority of the football players included in this review (*ACTN3*
361 = 48% & 33% respectively; *ACE* = 37% & 42% respectively). Thus, research is still required on players
362 of diverse geographical ancestry. Thirdly, the division of players into PRO and NP categories was
363 chosen to circumvent the well-known issues surrounding what constitutes 'eliteness' in sport; however,
364 the PRO level still encompasses substantial disparities in standards of play (e.g., English Premier
365 League vs. English Football League Two). As such, this makes it difficult to objectively quantify player
366 ability and consequently associate the findings with specific levels of performance. Finally, the on-field
367 positions of footballers were rarely reported in the included studies. This is important considering the
368 previously reported inter-positional associations between the *ACTN3* R577X and *ACE* I/D
369 polymorphism and football players, such as forwards and goalkeepers possessing significantly higher
370 frequencies of the *ACTN3* R allele and *ACE* D allele, respectively⁴². Therefore, it is unknown whether
371 the associations in this review were influenced by the number of players included in each study relative
372 to their on-field positions.

373 **4.4 Practical Applications**

374 Limited evidence exists supporting the practical application of genetic information with athlete
375 development. For example, it has been reported that individuals possessing the *ACTN3* RR and *ACE*
376 DD genotypes may have an improved adaptive response in strength and power with heavy resistance
377 training^{77,78}. As such, Kikuchi and Nakazato⁷⁹ suggested that individuals possessing power-orientated
378 genetic variants, such as *ACTN3* RR, may benefit more from resistance training consisting of high
379 weights with low-repetitions for strength and power. Jones and colleagues⁸⁰ investigated this theory
380 and reported that in 39 football players the *ACE* DD and *ACTN3* RR genotypes demonstrated a greater
381 improvement in countermovement jump performance in response to high-weight low-repetition
382 resistance training; whereas, the *ACE* II and *ACTN3* XX genotypes demonstrated a greater improvement
383 with low-load high-repetition resistance training. However, this study comprised a small sample size,
384 which consequently increases the likelihood of type 1 error occurrence⁸¹. Furthermore, to the author's
385 knowledge, the results presented by Jones and colleagues⁸⁰ have yet to be replicated in an independent

386 cohort. Therefore, further intervention studies are required in order to establish a strong evidence base,
387 before practical recommendations can be proposed regarding the results of this review. However, once
388 a strong evidence base has been established which supports genetic-based programme design, this
389 review can be used alongside a number of other extensively evidenced/researched genotypes to form
390 the basis of genetic-based training. Indeed, studies have also showcased that differences in biomarkers
391 of muscle damage, hormones, and inflammatory responses, may be influenced by genotype variation
392 ^{82,83}. Therefore, the utilisation of genetic information in the future may not only aid in optimising
393 training adaptation, but also the planning of athlete workloads and recovery.

394 **5 Conclusion**

395 The results of this review provide further evidence that individual genetic variation likely contributes
396 towards athlete status. Our findings suggest that genetic variation can differentiate athletes of different
397 competitive playing statuses in a homogenous team-sport cohort. Specifically, this review has
398 showcased that the R allele and RR genotype of the *ACTN3* R577X polymorphism are overrepresented
399 in PRO football players; whereas the D allele and DD genotype of the *ACE* I/D polymorphism are
400 overrepresented in youth players. These overrepresentations may be explained by the association of the
401 *ACTN3* RR genotype and *ACE* DD genotype with power-orientated phenotypes and the relative
402 contribution of these power-orientated phenotypes to success in football. As such, the *ACTN3* R577X
403 and *ACE* I/D polymorphisms are likely (albeit relatively minor) contributing factors which influence
404 athlete status in football.

405 **Declarations**

406 **Acknowledgements** Not applicable

407 **Funding** No funding was received in support of this manuscript.

408 **Disclosure Statement** Alexander B. T. McAuley, David C. Hughes, Loukia G. Tsaprouni, Ian Varley,
409 Bruce Suraci, Thomas R. Roos, Adam J. Herbert, and Adam L. Kelly declare that they have no conflicts
410 of interest.

411 **Contributions** All authors contributed to the conception of the article. ABTM drafted the article and
412 performed the literature search and analysis. All authors contributed to interpretation of the
413 results and critically revised the work. All authors read and approved the final manuscript.

414 **Word Count** 5100

415 **References**

- 416 1. Beggs, A. H. *et al.* Cloning and characterization of two human skeletal muscle alpha-
417 actinin genes located on chromosomes 1 and 11. *J. Biol. Chem.* **267**, 9281–9288 (1992).
- 418 2. Mills, M. *et al.* Differential expression of the actin-binding proteins, alpha-actinin-2 and -
419 3, in different species: implications for the evolution of functional redundancy. *Hum.*
420 *Mol. Genet.* **10**, 1335–1346 (2001).
- 421 3. Garton, F. C. *et al.* α -Actinin-3 deficiency alters muscle adaptation in response to
422 denervation and immobilization. *Hum. Mol. Genet.* **23**, 1879–1893 (2014).
- 423 4. North, K. N. *et al.* A common nonsense mutation results in alpha-actinin-3 deficiency in
424 the general population. *Nat. Genet.* **21**, 353–354 (1999).
- 425 5. Yang, N. *et al.* ACTN3 genotype is associated with human elite athletic performance.
426 *Am. J. Hum. Genet.* **73**, 627–631 (2003).
- 427 6. Niemi, A.-K. & Majamaa, K. Mitochondrial DNA and ACTN3 genotypes in Finnish elite
428 endurance and sprint athletes. *Eur. J. Hum. Genet. EJHG* **13**, 965–969 (2005).
- 429 7. Papadimitriou, I. D., Papadopoulos, C., Kouvatsi, A. & Triantaphyllidis, C. The ACTN3
430 gene in elite Greek track and field athletes. *Int. J. Sports Med.* **29**, 352–355 (2008).
- 431 8. Roth, S. M. *et al.* The ACTN3 R577X nonsense allele is under-represented in elite-level
432 strength athletes. *Eur. J. Hum. Genet. EJHG* **16**, 391–394 (2008).
- 433 9. Druzhevskaya, A. M., Ahmetov, I. I., Astratenkova, I. V. & Rogozkin, V. A. Association
434 of the ACTN3 R577X polymorphism with power athlete status in Russians. *Eur. J. Appl.*
435 *Physiol.* **103**, 631–634 (2008).
- 436 10. Massidda, M., Vona, G. & Calò, C. M. Association between the ACTN3 R577X
437 polymorphism and artistic gymnastic performance in Italy. *Genet. Test. Mol. Biomark.*
438 **13**, 377–380 (2009).

- 439 11. Chiu, L.-L. *et al.* ACTN3 genotype and swimming performance in Taiwan. *Int. J. Sports*
440 *Med.* **32**, 476–480 (2011).
- 441 12. Eynon, N. *et al.* ACTN3 R577X polymorphism and Israeli top-level athletes. *Int. J.*
442 *Sports Med.* **30**, 695–698 (2009).
- 443 13. Ahmetov, I. I. *et al.* The dependence of preferred competitive racing distance on muscle
444 fibre type composition and ACTN3 genotype in speed skaters. *Exp. Physiol.* **96**, 1302–
445 1310 (2011).
- 446 14. Ciężczyk, P. *et al.* Association of the ACTN3 R577X Polymorphism in Polish Power-
447 Orientated Athletes. *J. Hum. Kinet.* **28**, 55–61 (2011).
- 448 15. Mikami, E. *et al.* ACTN3 R577X genotype is associated with sprinting in elite Japanese
449 athletes. *Int. J. Sports Med.* **35**, 172–177 (2014).
- 450 16. Ma, F. *et al.* The association of sport performance with ACE and ACTN3 genetic
451 polymorphisms: a systematic review and meta-analysis. *PloS One* **8**, e54685 (2013).
- 452 17. Tharabenjasin, P., Pabalan, N. & Jarjanazi, H. Association of the ACTN3 R577X
453 (rs1815739) polymorphism with elite power sports: A meta-analysis. *PloS One* **14**,
454 e0217390 (2019).
- 455 18. Dzau, V. J. Circulating versus local renin-angiotensin system in cardiovascular
456 homeostasis. *Circulation* **77**, I4-13 (1988).
- 457 19. Munzenmaier, D. H. & Greene, A. S. Opposing actions of angiotensin II on
458 microvascular growth and arterial blood pressure. *Hypertens. Dallas Tex 1979* **27**, 760–
459 765 (1996).
- 460 20. Erdös, E. G. & Skidgel, R. A. The angiotensin I-converting enzyme. *Lab. Investig. J.*
461 *Tech. Methods Pathol.* **56**, 345–348 (1987).

- 462 21. Rigat, B. *et al.* An insertion/deletion polymorphism in the angiotensin I-converting
463 enzyme gene accounting for half the variance of serum enzyme levels. *J. Clin. Invest.* **86**,
464 1343–1346 (1990).
- 465 22. Danser, A. H. *et al.* Angiotensin-converting enzyme in the human heart. Effect of the
466 deletion/insertion polymorphism. *Circulation* **92**, 1387–1388 (1995).
- 467 23. Zhang, B. *et al.* The I allele of the angiotensin-converting enzyme gene is associated with
468 an increased percentage of slow-twitch type I fibers in human skeletal muscle. *Clin.*
469 *Genet.* **63**, 139–144 (2003).
- 470 24. Gayagay, G. *et al.* Elite endurance athletes and the ACE I allele--the role of genes in
471 athletic performance. *Hum. Genet.* **103**, 48–50 (1998).
- 472 25. Montgomery, H. E. *et al.* Human gene for physical performance. *Nature* **393**, 221–222
473 (1998).
- 474 26. Myerson, S. *et al.* Human angiotensin I-converting enzyme gene and endurance
475 performance. *J. Appl. Physiol. Bethesda Md 1985* **87**, 1313–1316 (1999).
- 476 27. Alvarez, R. *et al.* Genetic variation in the renin-angiotensin system and athletic
477 performance. *Eur. J. Appl. Physiol.* **82**, 117–120 (2000).
- 478 28. Nazarov, I. B. *et al.* The angiotensin converting enzyme I/D polymorphism in Russian
479 athletes. *Eur. J. Hum. Genet. EJHG* **9**, 797–801 (2001).
- 480 29. Scanavini, D., Bernardi, F., Castoldi, E., Conconi, F. & Mazzoni, G. Increased frequency
481 of the homozygous II ACE genotype in Italian Olympic endurance athletes. *Eur. J. Hum.*
482 *Genet.* **10**, 576–577 (2002).
- 483 30. Turgut, G., Turgut, S., Genc, O., Atalay, A. & Atalay, E. O. The angiotensin converting
484 enzyme I/D polymorphism in Turkish athletes and sedentary controls. *Acta Medica*
485 *(Hradec Kralove)* **47**, 133–136 (2004).

- 486 31. Cieszczyk, P., Krupecki, K., Maciejewska, A. & Sawczuk, M. The angiotensin
487 converting enzyme gene I/D polymorphism in Polish rowers. *Int. J. Sports Med.* **30**, 624–
488 627 (2009).
- 489 32. Min, S.-K. *et al.* Is there a gender difference between ACE gene and race distance? *Appl.*
490 *Physiol. Nutr. Metab. Physiol. Appl. Nutr. Metab.* **34**, 926–932 (2009).
- 491 33. Shenoy, S., Tandon, S., Sandhu, J. & Bhanwer, A. S. Association of Angiotensin
492 Converting Enzyme gene Polymorphism and Indian Army Triathletes Performance.
493 *Asian J. Sports Med.* **1**, 143–150 (2010).
- 494 34. Weyerstraß, J., Stewart, K., Wesselius, A. & Zeegers, M. Nine genetic polymorphisms
495 associated with power athlete status - A Meta-Analysis. *J. Sci. Med. Sport* **21**, 213–220
496 (2018).
- 497 35. Bangsbo, J., Mohr, M. & Krstrup, P. Physical and metabolic demands of training and
498 match-play in the elite football player. *J. Sports Sci.* **24**, 665–674 (2006).
- 499 36. Mallo, J., Mena, E., Nevado, F. & Paredes, V. Physical Demands of Top-Class Soccer
500 Friendly Matches in Relation to a Playing Position Using Global Positioning System
501 Technology. *J. Hum. Kinet.* **47**, 179–188 (2015).
- 502 37. Buchheit, M., Mendez-villanueva, A., Simpson, B. M. & Bourdon, P. C. Repeated-sprint
503 sequences during youth soccer matches. *Int. J. Sports Med.* **31**, 709–716 (2010).
- 504 38. Dellal, A. *et al.* Comparison of physical and technical performance in European soccer
505 match-play: FA Premier League and La Liga. *Eur. J. Sport Sci.* **11**, 51–59 (2011).
- 506 39. Santiago, C. *et al.* ACTN3 genotype in professional soccer players. *Br. J. Sports Med.* **42**,
507 71–73 (2008).
- 508 40. Ulucan, K., Sercan, C. & Biyikli, T. Distribution of angiotensin-1 converting enzyme
509 insertion/deletion and α -actinin-3 codon 577 polymorphisms in Turkish male soccer
510 players. *Genet. Epigenetics* **7**, 1–4 (2015).

- 511 41. Galeandro, V. *et al.* ACTN3/ACE genotypes and mitochondrial genome in professional
512 soccer players performance. *J. Biol. Regul. Homeost. Agents* **31**, 207–213 (2017).
- 513 42. Egorova, E. S. *et al.* The polygenic profile of Russian football players. *J. Sports Sci.* **32**,
514 1286–1293 (2014).
- 515 43. Honarpour, A., Mohseni, M., Ghavidel Hajiagha, S., Irani, S. & Najmabadi, H.
516 Investigation of the relationship between a genetic polymorphism in ACTN3 and elite
517 sport performance among Iranian soccer players. *Iran. Rehabil. J.* **15**, 149–154 (2017).
- 518 44. Coelho, D. B. *et al.* Evidence for a role of ACTN3 R577X polymorphism in football
519 player’s career progression. *Int. J. Sports Med.* **39**, 1088–1093 (2018).
- 520 45. Wang, G. *et al.* Genomics of elite sporting performance: what little we know and
521 necessary advances. *Adv. Genet.* **84**, 123–149 (2013).
- 522 46. Monnerat, G., Maior, A. S., Tannure, M., Back, L. K. F. C. & Santos, C. G. M. Single-
523 nucleotide-polymorphism-panel population-genetics approach based on the 1000
524 genomes database and elite soccer players. *Int. J. Sports Physiol. Perform.* **14**, 711–717
525 (2019).
- 526 47. Sahoo, G. S., Little, J. & Higgins, J. P. T. Systematic reviews of genetic association
527 studies. Human Genome Epidemiology Network. *PLoS Med.* **6**, e28 (2009).
- 528 48. McAuley, A. B. T. *et al.* Genetic association research in football: a systematic review.
529 *Eur. J. Sport Sci.* 1–39 (2020) doi:10.1080/17461391.2020.1776401.
- 530 49. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for
531 systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* **6**, e1000097–
532 e1000097 (2009).
- 533 50. Salanti, G., Amountza, G., Ntzani, E. E. & Ioannidis, J. P. A. Hardy-Weinberg
534 equilibrium in genetic association studies: an empirical evaluation of reporting,
535 deviations, and power. *Eur. J. Hum. Genet. EJHG* **13**, 840–848 (2005).

- 536 51. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
537 Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* **57**, 289–300
538 (1995).
- 539 52. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected
540 by a simple, graphical test. *BMJ* **315**, 629–634 (1997).
- 541 53. Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H. & Olkin, I. The case of the
542 misleading funnel plot. *BMJ* **333**, 597–600 (2006).
- 543 54. Whitehead, A. & Whitehead, J. A general parametric approach to the meta-analysis of
544 randomized clinical trials. *Stat. Med.* **10**, 1665–1677 (1991).
- 545 55. Viechtbauer, W. & Cheung, M. W.-L. Outlier and influence diagnostics for meta-
546 analysis. *Res. Synth. Methods* **1**, 112–125 (2010).
- 547 56. Martorell-Marugan, J., Toro-Dominguez, D., Alarcon-Riquelme, M. E. & Carmona-Saez,
548 P. MetaGenyo: a web tool for meta-analysis of genetic association studies. *BMC*
549 *Bioinformatics* **18**, (2017).
- 550 57. Massidda, M., Scorcu, M. & Calò, C. M. New genetic model for predicting phenotype
551 traits in sports. *Int. J. Sports Physiol. Perform.* **9**, 554–560 (2014).
- 552 58. La Montagna, R. *et al.* Genomic analysis reveals association of specific SNPs with
553 athletic performance and susceptibility to injuries in professional soccer players. *J. Cell.*
554 *Physiol.* (2019) doi:10.1002/jcp.29118.
- 555 59. Gineviciene, V., Jakaitiene, A., Tubelis, L. & Kucinskas, V. Variation in the ACE,
556 PPARGC1A and PPARA genes in Lithuanian football players. *Eur. J. Sport Sci.* **14**,
557 S289-295 (2014).
- 558 60. Andreeva, L. *et al.* Angiotensin-converting enzyme genotypes, allele frequency, C-
559 reactive protein, uric acid in female Zulu South African soccer, netball and Bulgarian
560 soccer players. *Afr. J. Phys. Health Educ. Recreat. Dance* **20**, 153–163 (2014).

- 561 61. Stølen, T., Chamari, K., Castagna, C. & Wisløff, U. Physiology of soccer: an update.
562 *Sports Med. Auckl. NZ* **35**, 501–536 (2005).
- 563 62. Bradley, P. S. *et al.* High-intensity running in English FA Premier League soccer
564 matches. *J. Sports Sci.* **27**, 159–168 (2009).
- 565 63. Little, T. & Williams, A. G. Specificity of acceleration, maximum speed, and agility in
566 professional soccer players. *J. Strength Cond. Res.* **19**, 76–78 (2005).
- 567 64. Oliver, J. L., Armstrong, N. & Williams, C. A. Relationship between brief and prolonged
568 repeated sprint ability. *J. Sci. Med. Sport* **12**, 238–243 (2009).
- 569 65. Pimenta, E. M. *et al.* Effect of ACTN3 gene on strength and endurance in soccer players.
570 *J. Strength Cond. Res.* **27**, 3286–3292 (2013).
- 571 66. Dionísio, T. J. *et al.* The influence of genetic polymorphisms on performance and cardiac
572 and hemodynamic parameters among Brazilian soccer players. *Appl. Physiol. Nutr.*
573 *Metab. Physiol. Appl. Nutr. Metab.* **42**, 596–604 (2017).
- 574 67. Swann, C., Moran, A. & Piggott, D. Defining elite athletes: Issues in the study of expert
575 performance in sport psychology. *Psychol. Sport Exerc.* **16**, 3–14 (2015).
- 576 68. Kirkland, A. & O’Sullivan, M. There Is No Such Thing as an International Elite Under-9
577 Soccer Player. *J. Sports Sci. Med.* **17**, 686–688 (2018).
- 578 69. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity
579 biology. *Nature* **518**, 197–206 (2015).
- 580 70. Gil, S., Ruiz, F., Irazusta, A., Gil, J. & Irazusta, J. Selection of young soccer players in
581 terms of anthropometric and physiological factors. *J. Sports Med. Phys. Fitness* **47**, 25–
582 32 (2007).
- 583 71. Waldron, M. & Murphy, A. A comparison of physical abilities and match performance
584 characteristics among elite and subelite under-14 soccer players. *Pediatr. Exerc. Sci.* **25**,
585 423–434 (2013).

- 586 72. Yang, N. *et al.* The ACTN3 R577X polymorphism in East and West African athletes.
587 *Med. Sci. Sports Exerc.* **39**, 1985–1988 (2007).
- 588 73. Scott, R. A. *et al.* ACTN3 and ACE genotypes in elite Jamaican and US sprinters. *Med.*
589 *Sci. Sports Exerc.* **42**, 107–112 (2010).
- 590 74. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
591 *Nature* **526**, 68–74 (2015).
- 592 75. Barbosa, F. B. *et al.* Ancestry Informative Marker Panel to Estimate Population
593 Stratification Using Genome-wide Human Array. *Ann. Hum. Genet.* **81**, 225–233 (2017).
- 594 76. Saloum de Neves Manta, F. *et al.* Revisiting the genetic ancestry of Brazilians using
595 autosomal AIM-Indels. *PloS One* **8**, e75145 (2013).
- 596 77. Delmonico, M. J. *et al.* Alpha-actinin-3 (ACTN3) R577X polymorphism influences knee
597 extensor peak power response to strength training in older men and women. *J. Gerontol.*
598 *A. Biol. Sci. Med. Sci.* **62**, 206–212 (2007).
- 599 78. Erskine, R. M., Williams, A. G., Jones, D. A., Stewart, C. E. & Degens, H. The
600 individual and combined influence of ACE and ACTN3 genotypes on muscle phenotypes
601 before and after strength training. *Scand. J. Med. Sci. Sports* **24**, 642–648 (2014).
- 602 79. Kikuchi, N. & Nakazato, K. Effective utilization of genetic information for athletes and
603 coaches: focus on ACTN3 R577X polymorphism. *J. Exerc. Nutr. Biochem.* **19**, 157–164
604 (2015).
- 605 80. Jones, N. *et al.* A genetic-based algorithm for personalized resistance training. *Biol. Sport*
606 **33**, 117–126 (2016).
- 607 81. Karanikolou, A., Wang, G. & Pitsiladis, Y. Letter to the editor: A genetic-based
608 algorithm for personalized resistance training. *Biol. Sport* **34**, 31–33 (2017).
- 609 82. Pimenta, E. M. *et al.* The ACTN3 genotype in soccer players in response to acute
610 eccentric training. *Eur. J. Appl. Physiol.* **112**, 1495–1503 (2012).

611 83. Coelho, D. B. *et al.* Alpha-Actinin-3 R577X Polymorphism Influences Muscle Damage
612 and Hormonal Responses After a Soccer Game. *J. Strength Cond. Res.* **33**, 2655–2664
613 (2019).
614




Figure 1. Flow diagram of systematic search process.

Table 1. Statistical analysis of all studies investigating the *ACTN3* R577X polymorphism (n = 15)

Case-Control							
Model	Association test			Heterogeneity		Bias	
	OR	95% CI	P	P	I²	Egger's	
Allele contrast	1.30	1.15-1.46	<0.001	0.68	0.00	0.88	
Recessive	1.42	1.20-1.68	<0.001	0.22	0.24	0.87	
Dominant	1.35	1.06-1.72	0.016	0.33	0.13	0.97	
Over-dominant	0.84	0.66-1.07	0.16	0.05	0.45	0.93	
RR vs. XX	1.67	1.28-2.17	<0.001	0.63	0.00	0.98	
RR vs. RX	1.38	1.07-1.78	0.013	0.08	0.41	0.76	
RX vs. XX	1.17	0.90-1.51	0.23	0.11	0.38	0.92	
Case-Control & Cohort							
Allele contrast	1.26	1.15-1.38	<0.001	0.72	0.00	0.48	
Recessive	1.31	1.15-1.50	<0.001	0.23	0.18	0.89	
Dominant	1.40	1.17-1.69	<0.001	0.49	0.00	0.64	
Over-dominant	0.93	0.78-1.12	0.45	0.05	0.38	0.75	
RR vs. XX	1.60	1.31-1.96	<0.001	0.72	0.00	0.62	
RR vs. RX	1.23	1.02-1.49	0.029	0.08	0.34	0.83	
RX vs. XX	1.29	1.06-1.57	0.010	0.18	0.24	0.69	
PRO vs. NP							
Allele contrast	PRO	1.35	1.18-1.53	<0.001	0.77	0.00	0.34
	NP	1.07	0.90-1.27	0.44	0.90	0.00	0.30
Recessive	PRO	1.48	1.23-1.77	<0.001	0.30	0.14	0.70
	NP	1.00	0.78-1.29	0.97	0.74	0.00	0.46
Dominant	PRO	1.40	1.09-1.81	0.010	0.16	0.30	0.83
	NP	1.27	0.91-1.76	0.16	1.00	0.00	0.34
Over-dominant	PRO	0.84	0.63-1.12	0.24	0.020	0.51	0.89
	NP	1.13	0.89-1.43	0.33	0.79	0.00	0.66
RR vs. XX	PRO	1.77	1.34-2.34	<0.001	0.57	0.00	0.61
	NP	1.22	0.84-1.76	0.29	0.95	0.00	0.21
RR vs. RX	PRO	1.41	1.07-1.86	0.014	0.07	0.40	0.98
	NP	0.94	0.72-1.23	0.68	0.72	0.00	0.52
RX vs. XX	PRO	1.22	0.79-1.87	0.36	0.028	0.50	0.91
	NP	1.30	0.92-1.84	0.14	0.99	0.00	1.00
Caucasian & Brazilian							
Allele contrast	Caucasian	1.32	1.14-1.53	<0.001	0.39	0.05	0.73
	Brazilian	1.23	1.07-1.41	0.003	0.45	0.00	0.47
Recessive	Caucasian	1.41	1.14-1.74	0.001	0.11	0.42	0.67
	Brazilian	1.19	0.98-1.44	0.07	0.64	0.00	0.69
Dominant	Caucasian	1.49	1.11-2.00	0.008	0.79	0.00	0.82
	Brazilian	1.52	1.15-1.99	0.003	0.17	0.35	0.92
Over-dominant	Caucasian	0.91	0.75-1.12	0.38	0.11	0.42	0.69
	Brazilian	1.07	0.89-1.29	0.48	0.59	0.00	0.45
RR vs. XX	Caucasian	1.71	1.24-2.36	0.001	0.60	0.00	0.60
	Brazilian	1.61	1.19-2.16	0.002	0.23	0.27	0.94
RR vs. RX	Caucasian	1.36	0.96-1.92	0.08	0.08	0.47	0.61
	Brazilian	1.08	0.88-1.32	0.46	0.66	0.00	0.85
RX vs. XX	Caucasian	1.34	0.98-1.83	0.06	0.61	0.00	0.97
	Brazilian	1.48	1.10-1.98	0.009	0.17	0.35	0.98

Note. Allele contrast (R vs. X); Recessive (RR vs. RX+XX); Dominant (RR+RX vs. XX); Over-dominant (RX vs. RR+XX); OR = Odds Ratio; CI = Confidence Interval; PRO = Professional; NP = Non-Professional.

Table 2. Statistical analysis of all studies investigating the *ACE* I/D polymorphism (n = 17)

Case-Control							
Model	Association test			Heterogeneity		Bias	
	OR	95% CI	P	P	I ²	Egger's	
Allele contrast	0.88	0.73-1.07	0.21	0.001	0.61	0.16	
Recessive	0.84	0.69-1.03	0.09	0.44	0.01	0.72	
Dominant	0.84	0.62-1.15	0.28	<0.001	0.66	0.09	
Over-dominant	0.93	0.74-1.16	0.51	0.040	0.44	0.04	
II vs. DD	0.82	0.58-1.17	0.27	0.025	0.47	0.19	
II vs. ID	0.98	0.79-1.21	0.82	0.65	0.00	0.27	
ID vs. DD	0.84	0.62-1.14	0.26	0.002	0.60	0.08	
Case-Control & Cohort							
Allele contrast	0.87	0.75-1.02	0.09	0.004	0.53	0.10	
Recessive	0.86	0.72-1.03	0.10	0.69	0.00	0.69	
Dominant	0.82	0.63-1.07	0.14	<0.001	0.62	0.05	
Over-dominant	0.90	0.73-1.10	0.31	0.019	0.45	0.03	
II vs. DD	0.79	0.60-1.05	0.10	0.08	0.34	0.12	
II vs. ID	1.00	0.83-1.22	0.97	0.75	0.00	0.21	
ID vs. DD	0.81	0.62-1.06	0.13	0.001	0.58	0.05	
PRO vs. NP							
Allele contrast	PRO	1.01	0.86-1.19	0.88	0.96	0.00	0.67
	NP	0.85	0.73-0.99	0.044	0.15	0.35	0.45
Recessive	PRO	0.97	0.72-1.29	0.82	0.99	0.00	0.99
	NP	0.88	0.65-1.18	0.39	0.20	0.29	0.38
Dominant	PRO	1.05	0.82-1.34	0.71	0.86	0.00	0.73
	NP	0.78	0.61-0.98	0.032	0.25	0.22	0.44
Over-dominant	PRO	1.07	0.85-1.34	0.57	0.81	0.00	0.62
	NP	0.86	0.69-1.07	0.18	0.22	0.27	0.95
II vs. DD	PRO	1.05	0.74-1.49	0.77	0.99	0.00	0.95
	NP	0.77	0.55-1.08	0.14	0.22	0.26	0.26
II vs. ID	PRO	0.94	0.69-1.27	0.69	0.98	0.00	0.85
	NP	0.97	0.71-1.33	0.85	0.20	0.28	0.51
ID vs. DD	PRO	1.05	0.80-1.36	0.73	0.80	0.00	0.55
	NP	0.76	0.59-0.97	0.030	0.38	0.07	0.56
Caucasian & Brazilian							
Allele contrast	Caucasian	0.81	0.57-1.14	0.23	0.004	0.74	0.04
	Brazilian	0.85	0.70-1.03	0.09	0.37	0.07	0.63
Recessive	Caucasian	0.75	0.57-1.00	0.05	0.61	0.00	0.50
	Brazilian	0.83	0.60-1.14	0.25	0.25	0.26	0.07
Dominant	Caucasian	0.75	0.42-1.34	0.34	<0.001	0.82	0.03
	Brazilian	0.77	0.55-1.06	0.11	0.17	0.38	0.73
Over-dominant	Caucasian	0.83	0.53-1.29	0.40	0.009	0.70	0.08
	Brazilian	1.05	0.64-1.71	0.85	0.018	0.67	0.29
II vs. DD	Caucasian	0.65	0.38-1.10	0.11	0.08	0.52	0.08
	Brazilian	0.80	0.52-1.22	0.29	0.31	0.17	0.58
II vs. ID	Caucasian	1.05	0.77-1.44	0.75	0.59	0.00	0.28
	Brazilian	0.88	0.63-1.23	0.45	0.10	0.48	0.19
ID vs. DD	Caucasian	0.76	0.41-1.42	0.39	<0.001	0.82	0.07
	Brazilian	0.82	0.47-1.42	0.48	0.09	0.51	0.57

Note. Allele contrast (I vs. D); Recessive (II vs. ID+DD); Dominant (II+ID vs. DD); Over-dominant (ID vs.

II+DD); OR = Odds Ratio; CI = Confidence Interval; PRO = Professional; NP = Non-Professional.




Figure 2. Forest plots of significant PRO and NP comparison models. (A) *ACTN3* R vs. X allele in PROs; (B) *ACTN3* RR vs. RX+XX in PROs; (C) *ACE* D vs. I allele in NPs; (D) *ACE* DD vs. DI+II in NPs.